GSK's Garnier gets $4.9M handshake

When Jean-Pierre Garnier (photo) makes his exit from GlaxoSmithKline next month, he'll walk away with the promise of a $4.9 million options bonus that could pay off sometime in 2010. News of the golden handshake comes as U.K. investors are growing riled at the practice, The Times of London reports. Marks & Spencer is paying its chairman almost $1 million for stepping aside, and BT's chief is getting more than $1.5 million when he quits, plus another $7.8 million in performance options. Also, Garnier has run into investor revolt over his pay before: in 2002, shareholders voted down an $18 million pay package at GSK's annual meeting.

- see the story in the Times
- see the Pharmalot item

Related Articles:
GSK's Garnier to join Dubai equity firm. Garnier report
GSK taps Witty as next CEO. GSK report
GSK CEO also-rans may get on board. GSK report
At GSK, a public race for the top spot. GSK report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

A phase 1 study of the Inlyta-Keytruda regimen, which bears a first-line nod for kidney cancer, got the ax along with several Bavencio tests.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.